{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:18:37Z","timestamp":1772025517231,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology of Taiwan","doi-asserted-by":"crossref","award":["MOST 110-2628-B-371-001"],"award-info":[{"award-number":["MOST 110-2628-B-371-001"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Changhua Christian Hospital Research Foundation","award":["109-CCH-IRP-028"],"award-info":[{"award-number":["109-CCH-IRP-028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Aims<\/jats:title>\n                    <jats:p>Entecavir (ETV) can suppress chronic hepatitis B (CHB) virus replication as a standard of treatment drugs. For the treatment of CHB, affordable generic drugs may be more widely used in developing and undeveloped countries. However, there is little real-world data regarding the clinical efficacy of switching from entecavir-brand-name drugs (ETV-Brand) to entecavir generic drugs (ETV-Generic) with 0.5\u00a0mg once daily. The aim of the study was to evaluate the antiviral activity and safety of ETV-Generic in comparison to ETV-Brand in CHB-patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center, retrospective, 175 treatment-na\u00efve\u2014CHB-patients were assigned to receive 0.5\u00a0mg of ETV-Brand per day for a least 2\u00a0years and then switched to ETV-Generic for 6\u00a0months for analysis. The primary efficacy endpoint was a sustained virological response in comparison of the rate of undetectable serum Hepatitis B deoxyribonucleic acid (HBV DNA) as the sustained virologic response at baseline and 6\u00a0months after switching. Secondary efficacy endpoints were the comparison of the alanine aminotransferase (ALT) levels between before and after switching and ALT normalization. Renal safety consideration was reported on changing the estimated glomerular filtration rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From baseline to 6\u00a0months, the rate of undetectable HBV DNA and ALT levels remained stable as compared ETV-Brand period with ETV-Generic for 6\u00a0months. The rate of undetectable HBV DNA were 81.1%in ETV-Brand versus 88.0%in ETV-Generic (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05 CI 0.1\u201313.5%). ALT levels were 27.2\u00a0IU\/L (CI 24.8\u201329.6\u00a0IU\/L) in ETV-Brand versus 26.2\u00a0IU\/L (CI 24.0\u201328.4\u00a0IU\/L) in ETV-Generic (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.55). Both endpoints were not significantly different between ETV-Brand and ETV-Generic treatments. Kidney function did not significantly differ from ETV-Brand (80.8, interquartile range [IQR]: 66.6\u201395.3\u00a0mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      ) to ETV-Generic treatment period (80.3, IQR: 65.6\u201393.5\u00a0mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In treatment-na\u00efve CHB-patients, the efficacy and safety profiles of switching from ETV-Brand to ETV-Generic showed no difference. Concluding the ETV-Generic comes to exciting virologic responses and rare adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-022-02317-7","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T01:02:41Z","timestamp":1652144561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RETRACTED ARTICLE: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-na\u00efve chronic hepatitis B"],"prefix":"10.1186","volume":"22","author":[{"given":"Po-Ke","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"issue":"4","key":"2317_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1053\/jhep.2001.27810","volume":"34","author":"KM Breiner","year":"2001","unstructured":"Breiner KM, Schaller H, Knolle PA. Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms. Hepatology (Baltimore, MD). 2001;34(4):803\u20138.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"2317_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-22330-8_9","volume-title":"Hepatitis B virus in human diseases","author":"D Lavanchy","year":"2016","unstructured":"Lavanchy D, Kane M. Global epidemiology of hepatitis B virus infection. In: Liaw Y-F, Zoulim F, editors. Hepatitis B virus in human diseases. Cham: Springer; 2016. p. 187\u2013203."},{"issue":"4","key":"2317_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.patbio.2010.01.005","volume":"58","author":"M Kew","year":"2010","unstructured":"Kew M. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 2010;58(4):273\u20137.","journal-title":"Pathol Biol (Paris)"},{"issue":"3","key":"2317_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jvh.13452","volume":"28","author":"C Campbell","year":"2021","unstructured":"Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepatitis. 2021;28(3):493\u2013507.","journal-title":"J Viral Hepatitis"},{"key":"2317_CR5","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/ajt.15093","volume":"18","author":"Y Hutin","year":"2018","unstructured":"Hutin Y, Nasrullah M, Easterbrook P, Dongmo Nguimfack B, Burrone E, Averhoff F, et al. Access to treatment for hepatitis B virus infection\u2014worldwide, 2016. Am J Transplant. 2018;18:2595\u20138.","journal-title":"Am J Transplant"},{"key":"2317_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","volume":"6","author":"M Tan","year":"2020","unstructured":"Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;6:106\u201319.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"2317_CR7","first-page":"65","volume":"32","author":"K-J Lo","year":"1985","unstructured":"Lo K-J, Tsai Y, Lee S-D, Yeh C, Wang J, Chiang B, et al. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology. 1985;32(2):65\u20138.","journal-title":"Hepatogastroenterology"},{"key":"2317_CR8","first-page":"95","volume-title":"Hepatitis B control and its implementation. Epidemiology of Hepatitis B and Implementation of Immunoprophylaxis in Taiwan [in Han-Chinese] Taipei, Taiwan","author":"H Hsu","year":"1989","unstructured":"Hsu H. Hepatitis B control and its implementation. Epidemiology of Hepatitis B and Implementation of Immunoprophylaxis in Taiwan [in Han-Chinese] Taipei, Taiwan. Taiwan: Department of Health; 1989. p. 95\u2013105."},{"issue":"19","key":"2317_CR9","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1001\/jama.1987.03390190075023","volume":"257","author":"D-S Chen","year":"1987","unstructured":"Chen D-S, Hsu NH-M, Sung J-L, Hsu T-C, Hsu S-T, Kuo Y-T, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen\u2014carrier mothers. JAMA. 1987;257(19):2597\u2013603.","journal-title":"JAMA"},{"issue":"4","key":"2317_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jmv.1890180402","volume":"18","author":"HY Hsu","year":"1986","unstructured":"Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol. 1986;18(4):301\u20137.","journal-title":"J Med Virol"},{"issue":"11","key":"2317_CR11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jama.1996.03540110060032","volume":"276","author":"H-L Chen","year":"1996","unstructured":"Chen H-L, Chang M-H, Ni Y-H, Hsu H-Y, Lee P-l, Lee C-Y, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 1996;276(11):906\u20138.","journal-title":"JAMA"},{"key":"2317_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/liv.13001","volume":"36","author":"R Kumar","year":"2016","unstructured":"Kumar R, P\u00e9rez-del-Pulgar S, Testoni B, Leboss\u00e9 F, Zoulim F. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Liver Int. 2016;36:72\u20137.","journal-title":"Liver Int"},{"key":"2317_CR13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","volume":"75","author":"MG Martinez","year":"2021","unstructured":"Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections. J Hepatol. 2021;75:706\u201317.","journal-title":"J Hepatol"},{"key":"2317_CR14","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.2147\/DDDT.S149199","volume":"11","author":"JHK Do Young Kim","year":"2017","unstructured":"Do Young Kim JHK, Tak WY, Yeon JE, Lee JH, Yoon JH, Lee YJ, et al. Baracle\u00ae vs Baraclude\u00ae for 48 weeks in patients with treatment-na\u00efve chronic hepatitis B: a comparison of efficacy and safety. Drug Design Dev Ther. 2017;11:3145.","journal-title":"Drug Design Dev Ther"},{"issue":"9","key":"2317_CR15","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1128\/AAC.00599-13","volume":"57","author":"SA Jones","year":"2013","unstructured":"Jones SA, Murakami E, Delaney W, Furman P, Hu J. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother. 2013;57(9):4181\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2317_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139876","volume":"10","author":"M Toy","year":"2015","unstructured":"Toy M, Hutton DW, So SK. Cost-effectiveness and cost thresholds of generic and brand drugs in a national chronic hepatitis B treatment program in China. PLoS ONE. 2015;10(11): e0139876.","journal-title":"PLoS ONE"},{"issue":"1","key":"2317_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4166\/kjg.2020.0144","volume":"77","author":"YE Ahn","year":"2021","unstructured":"Ahn YE, Suh SJ, Kim TH, Jung YK, Yim HJ. Maintaining antiviral efficacy after switching to generic entecavir 1 mg for antiviral-resistant chronic hepatitis B. Korean J Gastroenterol. 2021;77(1):22\u20139.","journal-title":"Korean J Gastroenterol"},{"issue":"10","key":"2317_CR18","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","volume":"221","author":"Z Miao","year":"2020","unstructured":"Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677\u201387.","journal-title":"J Infect Dis"},{"issue":"2","key":"2317_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.gtc.2020.01.001","volume":"49","author":"H Razavi","year":"2020","unstructured":"Razavi H. Global epidemiology of viral hepatitis. Gastroenterol Clin N Am. 2020;49(2):179\u201389.","journal-title":"Gastroenterol Clin N Am"},{"issue":"Suppl 2","key":"2317_CR20","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1136\/gut.38.Suppl_2.S43","volume":"38","author":"M Lansang","year":"1996","unstructured":"Lansang M. Epidemiology and control of hepatitis B infection: a perspective from the Philippines. Asia Gut. 1996;38(Suppl 2):S43\u20137.","journal-title":"Asia Gut"},{"issue":"6","key":"2317_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"D Razavi-Shearer","year":"2018","unstructured":"Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, Van Damme P, Abbas Z, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383\u2013403.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2317_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1053\/j.gastro.2007.02.055","volume":"132","author":"YH Ni","year":"2007","unstructured":"Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology. 2007;132(4):1287\u201393.","journal-title":"Gastroenterology"},{"key":"2317_CR23","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0264-410X(99)00460-0","volume":"18","author":"K-Y Huang","year":"2000","unstructured":"Huang K-Y, Lin S-R. Nationwide vaccination: a success story in Taiwan. Vaccine. 2000;18:S35\u20138.","journal-title":"Vaccine"},{"key":"2317_CR24","doi-asserted-by":"crossref","unstructured":"Song JE, Park JY. Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B. Expert Opin Pharmacother. 2021 (just-accepted).","DOI":"10.1080\/14656566.2021.1967321"},{"key":"2317_CR25","first-page":"1","volume-title":"Hepatitis B virus infection","author":"H Li","year":"2020","unstructured":"Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, et al. Hepatitis B virus infection: overview. In: Tang H, editor., et al., Hepatitis B virus infection. Singapore: Springer; 2020. p. 1\u201316."},{"key":"2317_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/cid\/ciab405","volume":"74","author":"M Toy","year":"2021","unstructured":"Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-effectiveness of one-time universal screening for chronic hepatitis B infection in adults in the United States. Clin Infect Dis. 2021;74:210\u20137.","journal-title":"Clin Infect Dis"},{"key":"2317_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3389\/fpubh.2021.667253","volume":"9","author":"A Maisa","year":"2021","unstructured":"Maisa A, Kollan C, van B\u00f6mmel F, Cornberg M, Mauss S, Wedemeyer H, et al. Increasing number of individuals receiving hepatitis B nucleos (t) ide analogs therapy in Germany, 2008\u20132019. Front Public Health. 2021;9:574.","journal-title":"Front Public Health"},{"issue":"2","key":"2317_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S2055-6640(20)30484-2","volume":"1","author":"A Hill","year":"2015","unstructured":"Hill A, Gotham D, Cooke G, Bhagani S, Andrieux-Meyer I, Cohn J, et al. Analysis of minimum target prices for production of entecavir to treat hepatitis B in high-and low-income countries. J Virus Erad. 2015;1(2):103\u201310.","journal-title":"J Virus Erad"},{"key":"2317_CR29","first-page":"13","volume":"8","author":"J Wang","year":"2014","unstructured":"Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des Dev Ther. 2014;8:13.","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"2317_CR30","doi-asserted-by":"publisher","first-page":"1433987","DOI":"10.1080\/16549716.2018.1433987","volume":"11","author":"K Xu","year":"2018","unstructured":"Xu K, Liu L-M, Farazi PA, Wang H, Rochling FA, Watanabe-Galloway S, et al. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. Glob Health Action. 2018;11(1):1433987.","journal-title":"Glob Health Action"},{"issue":"9","key":"2317_CR31","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1377\/hlthaff.2020.00321","volume":"39","author":"KA Schulman","year":"2020","unstructured":"Schulman KA. Challenges in ensuring the quality of generic medicines. Health Aff. 2020;39(9):1643\u20136.","journal-title":"Health Aff"}],"updated-by":[{"DOI":"10.1186\/s12876-022-02483-8","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"record-id":"38759"},{"DOI":"10.1186\/s12876-022-02317-7","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000}},{"DOI":"10.1186\/s12876-022-02483-8","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000}}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02317-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02317-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02317-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:25:58Z","timestamp":1772022358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-022-02317-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2317"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02317-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"24 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12876-022-02483-8","URL":"https:\/\/doi.org\/10.1186\/s12876-022-02483-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Changhua Christian Hospital (CCH IRB No. 210202). All patients have signed an informed consent form, which has been certified by the Institutional Review Board, and we signed a confidentiality agreement to protect the rights and interests of patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no conflicts of interests in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}